Zydus Lifesciences Ltd. announced that its group entity, Zydus Medtech, has forged a strategic tie-up with Brazil-headquartered Braile Biomedica to market and distribute pioneering Transcatheter Aortic Valve Implantation (TAVI) technology in India and large European markets.
Key Highlights:
-
Strategic Collaboration: Zydus Medtech and Braile Biomedica will together introduce cutting-edge TAVI technology—a minimally invasive heart valve replacement procedure— to patients, with the vision of transforming aortic stenosis treatment.
-
Market Expansion: With the deal, Zydus Medtech will be responsible for regulatory approvals, commercialization, and distribution of TAVI devices across India and Europe, creating new opportunities for sophisticated cardiac care in both emerging and developed economies.
-
Medical Impact: TAVI provides a life-saving option for high-risk cardiac patients who cannot undergo open-heart surgery. The partnership is anticipated to make advanced cardiac therapies more accessible and enhance the outcome for thousands of patients.
-
Innovation Leadership: This collaboration demonstrates Zydus's focus on medtech innovation through the introduction of next-generation solutions to its growing product portfolio, enhancing its leadership in high-value healthcare technologies.
Leadership Insights:
A Zydus Lifesciences spokesperson said,
"Our partnership with Braile Biomedica brings cutting-edge heart valve technology to India and Europe, expanding our mission to provide innovative and affordable healthcare technologies to the world."
Outlook:
The commercialization of TAVI technology by Zydus Medtech will reshape the face of interventional cardiology in India and Europe, facilitating growth and improved patient care in the global medtech industry.
Source: Company press release, stock exchange filings, April 17, 2025.